Skip to main content

Covington & Burling has represented Tokyo-based Astellas Pharma on its $3 billion acquisition of U.S. drugmaker Audentes Therapeutics, which was advised by Fenwick & West.

According to Reuters, the acquisition marks the second biggest on record for Astellas after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion. Astellas expects the deal, which is subject to regulatory approval, including U.S. antitrust clearance, to close in the first quarter of 2020.

Reuters added that this sale was a push by Astellas Pharma to make genetic medicines a key area of growth. Gene therapies are one of the hottest areas of drug research and Astellas is offering $60 per share in cash for San Francisco-based Audentes.

Morgan Stanley and Centerview Partners are acting as financial advisors to Astellas and Audentes, respectively.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

R&T guides VietJet on historic $8 bln aviation deal

by Nimitt Dixit |

Singapore’s Rajah & Tann has advised Vietnam's VietJet Air on reaffirmation of its $8 billion deal with CFM International to acquire over 400 CFM advanced Leap 1B Aircraft Engines.

Deals

Davis Polk, Gibson Dunn advise on $2.3 bln Nippon Paint-AOC deal

by Asian Legal Business《亚洲法律杂志》 |

Davis Polk & Wardwell has advised Japanese paint manufacturer Nippon Paint on its $2.3 billion acquisition of U.S. chemicals formulator AOC from Lone Star Funds, which was represented by Gibson, Dunn & Crutcher.

Deals

Stephenson Harwood, Links advise on $349 mln SG-UK taxi deal

by Asian Legal Business《亚洲法律杂志》 |

Stephenson Harwood has advised Singaporean transport operator ComfortDelGro on its 269-million-pound ($349 million) acquisition of the British private hire cab and courier company Addison Lee, whose shareholders were represented by Linklaters.